PureTech Health PLC (PRTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PureTech Health PLC (PRTC) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.47 Million) by net assets ($305.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is PureTech Health PLC's balance sheet to measure how much of total assets are equity-financed.
PureTech Health PLC - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PureTech Health PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PureTech Health PLC cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
PureTech Health PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PureTech Health PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aarti Drugs Limited
NSE:AARTIDRUGS
|
0.104x |
|
Benz Mining Corp
F:1VU
|
-0.404x |
|
Kedge Construction Co Ltd
TW:2546
|
-0.331x |
|
Codere Online US Corp
NASDAQ:CDRO
|
0.181x |
|
Flagship Communities Real Estate Investment Trust
TO:MHC-U
|
0.030x |
|
Sohu.Com Inc
NASDAQ:SOHU
|
0.000x |
|
V.S.T Tillers Tractors Limited
NSE:VSTTILLERS
|
0.057x |
|
Qingdao Vland Biotech Co Ltd
SHG:603739
|
0.013x |
Annual Cash Flow Conversion Efficiency for PureTech Health PLC (2012–2025)
The table below shows the annual cash flow conversion efficiency of PureTech Health PLC from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see PRTC market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.68 Million | $-85.33 Million | -0.279x | +15.25% |
| 2024-12-31 | $407.93 Million | $-134.37 Million | -0.329x | -42.50% |
| 2023-12-31 | $458.23 Million | $-105.92 Million | -0.231x | +29.21% |
| 2022-12-31 | $547.59 Million | $-178.79 Million | -0.327x | -20.51% |
| 2021-12-31 | $584.15 Million | $-158.27 Million | -0.271x | -34.32% |
| 2020-12-31 | $653.54 Million | $-131.83 Million | -0.202x | -33.66% |
| 2019-12-31 | $650.40 Million | $-98.16 Million | -0.151x | +65.38% |
| 2018-12-31 | $166.97 Million | $-72.80 Million | -0.436x | +68.54% |
| 2017-12-31 | $64.00 Million | $-88.69 Million | -1.386x | -120.68% |
| 2016-12-31 | $92.41 Million | $-58.03 Million | -0.628x | -260.08% |
| 2015-12-31 | $164.05 Million | $-28.61 Million | -0.174x | -121.14% |
| 2014-12-31 | $133.69 Million | $-10.54 Million | -0.079x | -107.21% |
| 2013-12-31 | $-8.03 Million | $-8.77 Million | 1.093x | +152.49% |
| 2012-12-31 | $-3.35 Million | $-1.45 Million | 0.433x | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more